<html>

    <head>
  <meta charset="utf-8">
  <title>Urokinase, CX3CL1, CCL2, TRAIL and IL-18 induced by interferon-β treatment | Research Group at Uppsala University</title>
  <meta content="width=device-width, initial-scale=1" name="viewport">
  <meta content="Webflow" name="generator">
  <link href="/css/normalize.css" rel="stylesheet" type="text/css">
  <link href="/css/webflow.css" rel="stylesheet" type="text/css">
  <link href="/css/caramba.webflow.css?1723553503" rel="stylesheet" type="text/css">
  <script src="https://ajax.googleapis.com/ajax/libs/webfont/1.4.7/webfont.js"></script>
  <script type="text/javascript">
    WebFont.load({
      google: {
        families: ["Ubuntu:300,300italic,400,400italic,500,500italic,700,700italic","Raleway:regular,500,600,700,800,900"]
      }
    });
  </script>
  <script src="/js/modernizr.js" type="text/javascript"></script>
  <link href="/img/logos/caramba_header_logo.png" rel="shortcut icon" type="image/x-icon">
  <link href="/img/logos/caramba_header_logo.png" rel="apple-touch-icon">
  <script>
    (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
    (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
    m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
    })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');

    ga('create', 'UA-86146183-1', 'auto');
    ga('send', 'pageview');
  </script>
</head>


    
  <div class="section-header" id="section-header">
    <div class="section-header-container w-container">
      <div class="navbar w-nav" data-animation="default" data-collapse="medium" data-contain="1" data-doc-height="1" data-duration="400" data-no-scroll="1">
        <div class="navbar-container w-container">
          <a class="navbar-brand w-nav-brand" href="/">
              <img class="navbar-logo" src="/img/logos/rect205.png" height="50">
          </a>
          <div class="navbar-menubutton w-nav-button">
            <div class="w-icon-nav-menu"></div>
          </div>
          <a class="navbar-uulogo-link" href="https://www.medsci.uu.se/caramba/" target="_blank"><img class="navbar-uulogo-img" src="/img/logos/uulogo_64x64.png"></a>
          <nav class="navbar-menu w-nav-menu" role="navigation" style="float: right">
              
              <a class="navbar-link w-nav-link" href="/project/">Projects</a>
              
              <a class="navbar-link w-nav-link" href="/people/">People</a>
              
              <a class="navbar-link w-nav-link" href="/facility/">Facility</a>
              
              <a class="navbar-link w-nav-link" href="/publication/">Publications</a>
              
              
              
              <a class="navbar-link w-nav-link" href="/education/">Education</a>
              
              <a class="navbar-link w-nav-link" href="/about/">About</a>
              
          </nav>
        </div>
      </div>
    </div>
  </div>

              <div>
          <div class="section-content-container w-container content">

        <h1 style="font-size: 1.4em">Urokinase, CX3CL1, CCL2, TRAIL and IL-18 induced by interferon-β treatment</h1>
        <p><a href="/publication">&larr; Back to publications</a></p>

        <p>Published: 2021-02-24</p>

        <h4>Formatted citation</h4>
        <p>
            Zhukovsky C, Herman S, Wiberg A, Cunningham JL, Kultima K, Burman J..
            <a href="http://dx.doi.org/10.1111/ane.13400" target="_blank">Urokinase, CX3CL1, CCL2, TRAIL and IL-18 induced by interferon-β treatment</a>.
            <br><em>Acta Neurol Scand</em>.
             (2021).
            DOI: <a href="http://dx.doi.org/10.1111/ane.13400" target="_blank">10.1111/ane.13400</a>
            
        </p>
        <h4>Abstract</h4>
        <p>OBJECTIVE: To identify serum proteins associated with MS and affected by interferon beta treatment. METHODS: Plasma samples from 29 untreated relapsing-remitting MS patients and 15 healthy controls were investigated with a multiplexed panel containing 92 proteins related to inflammation. Follow-up samples were available from 13 patients at 1 and 3xa0months after initiation of treatment with interferon beta-1a. RESULTS: Ten proteins were differentially expressed in MS patients. Five of these were altered by treatment with IFN-β 1a: uPA, CX3CL1, CCL2, TRAIL and IL18. CONCLUSION: CCL2 and TRAIL were confirmed to be modulated with interferon beta treatment in MS. As novel findings, we now report that uPA and CX3CL1 were differentially expressed in MS and increased after IFN-beta-1a treatment. Conflicting results have been reported on how interferon beta affects IL-18.</p>

            </div>
</div>

      <div class="section-footer">
    <div class="section-footer-container w-container">
        
        <div class="footer-text">
            <p>
            <strong>CARAMBA Research Group</strong><br>
            Department of Medical Sciences<br>
            Uppsala University, Sweden<br>
            GitHub: <a href="https://github.com/caramba-uu">github.com/caramba</a>
            </p>
        </div>
    </div>
  </div>

  <script src="https://ajax.googleapis.com/ajax/libs/jquery/2.2.0/jquery.min.js" type="text/javascript"></script>
  <script src="/js/webflow.js" type="text/javascript"></script>
  
</body>
</html>

